Comparing mainstream claims in science and technology and received wisdom in society with the published record, we defend honest, accomplished, independent minded and often heroic scientists (Peter Duesberg, Serge Lang, Harvey Bialy, Kary Mullis, Henry Bauer, Jim Watson, Peter Medawar, Erwin Chargaff, Richard Feynman, Linus Pauling, James Hansen, Fred Singer, Richard Lindzer, Rainer Plaga, Otto Rossler, Michio Kaku, David Rasnick, Rebecca Culshaw, Ernst Krebs, Mark Leggett, Adrian Kent) and their good science against the censorship, mudslinging, false arguments, ad hominem propaganda, overwhelming group prejudice and internal science politics of the paradigm wars of cancer, HIV/AIDS, evolution, global warming, collider physics, health, medicine and nutrition, as well as from time to time promoting truth in personal technology by identifying items of genuinely high quality from those whose reputation is unjustly magnified in the media.
This publication aims to measure truth only by the professional and scholarly literature in peer reviewed journals, well researched books, and the investigative reporting and reviews of thoughtful and informed if often unconventional academics, philosophers, researchers, scholars, authors, and journalists (John Lauritsen, Celia Farber, Liam Scheff, Robert Houston, Claus Jensen, Anthony Liversidge, James Blodgett, Jim Tankersley, John Tierney, Bob Herbert, Dennis Overbye, Marcus Cohen, Gary Null, Walter Wagner, Luis Sancho, Toby Ord and Eric Johnson) too often scorned, shortchanged or damned by publicly irresponsible scientists and other authorities living off the status quo. 
I have never made but one prayer to God, a very short one: “O Lord make my enemies ridiculous.” And God granted it. – VoltaireSelf serving alarm at the Fierce Virus
The enthusiasm with which the scientists and medical workers in AIDS raise alarms is something to behold. No more striking example has taken place than the report last week of a fantastic new “nightmare” evolution of HIV into a version which has almost no latent period, and is resistant to nearly all current medications. This remarkable supposed discovery was based on a single example detected in a single patient.
This is precisely what scientists like to call an “anecdotal example”, and warn against taking too seriously. Obviously it is no occasion to call a press conference and trumpet the news to the skies as one more example of American medicine on guard, as it were, to new and lethal threats.
The story on Tuesday (April 21) written by Larry Altman and Marc Santora in the New York Times was at first more surprising, in fact, since it poo pooed the whole thing exactly on that basis. The headline read Alarm Over Single AIDS Case Is Challenged by Questioners and it reported some unexpected skepticism on the part of other disease experts, who felt that the Department had gone off half-cocked.
“One group of scientists not involved in the research was quick to dismiss the news as isolated to one man and unworthy of alarm. Other scientists said not enough research had been done to warrant a public health announcement, and accused Dr. Frieden of excessive haste.”
Close inspection of the story reveals, however, that it was not so much that scientific sanity had prevailed over the usual fund-siphoning alarmism, but turf envy.
“Longstanding rivalries among top AIDS researchers resurfaced, and one of the researchers who discovered the possible strain was accused of using a test developed by a company to which he had close ties.”
In fact, the story prompted a refreshing piece of realism from an official at AMFAR, an organization not known for quieting alarmism in the past.
“”The old jealousies, rivalries and big egos,” said Kevin Robert Frost, vice president of the American Foundation for AIDS Research, when asked why the response was so furious. “Scientists in general react negatively to news by press conference.”"
Meanwhile, AIDS skeptics pointed out an obvious fact. The rapid decline of the patient concerned was not unexpected in the wake of his enthusiastic imbibing of crystal methamphetamine as his drug of choice for months.
The full item:
Alarm Over Single AIDS Case Is Challenged by Questioners
New York Times
21 February 2005
By MARC SANTORA and LAWRENCE K. ALTMAN
New York City’s health commissioner, Thomas R. Frieden, had barely stepped away from the microphone on Feb. 11 after announcing the discovery of a possibly new and deadly H.I.V. strain when the storm started. More than a week later, it has not abated.
One group of scientists not involved in the research was quick to dismiss the news as isolated to one man and unworthy of alarm. Other scientists said not enough research had been done to warrant a public health announcement, and accused Dr. Frieden of excessive haste.
Gay activists worried that Dr. Frieden’s use of the announcement to emphasize safe-sex practices would set up gay men as culprits, reviving a concern as old as the disease. Longstanding rivalries among top AIDS researchers resurfaced, and one of the researchers who discovered the possible strain was accused of using a test developed by a company to which he had close ties.
To those who expect government officials to keep diseases at bay, it might seem surprising that a public health announcement about a deadly virus would be attacked, but AIDS is not like tuberculosis or polio. From the moment that H.I.V. was discovered, it caused political chasms and
profound disagreements among experts, and in recent weeks the virus seemed to be proving that it could still be treacherous and surprising, both as a deadly disease and a political fuse.
“The old jealousies, rivalries and big egos,” said Kevin Robert Frost, vice president of the American Foundation for AIDS Research, when asked why the response was so furious. “Scientists in general react negatively to news by press conference.”
At one level, the reaction illustrates the intense competition among scientists and their institutions to communicate new findings and get credit, crucial in obtaining money to expand their research. Many experts have been involved in the field for years, and in some cases their professional disagreements have developed into the animosities and outright personal hatreds that are common in academia.
Nonetheless, scientists, skeptics by nature and training, have a fundamentally different role than public health officials, who often have to take emergency measures to stop the spread of disease. As a result, some research scientists said the appearance of a possible drug-resistant and virulent strain of the virus in one 46-year-old man meant little. The man’s immune system might have been compromised by the crystal methamphetamine he had taken, they said, or the virus could have rapidly led to full-blown AIDS for other reasons that needed additional investigation before the public was alerted.
“This is a nonstory,” Dr. Paul Volberding, director of the Center for AIDS Research at the University of California, San Francisco, said in an interview, noting that the pace of change from H.I.V. to AIDS depended not only on the virus but also the patient. “There have been many cases
of rapid progression. The New York case is only that, a case report.”
But public health officials said that with the battle against AIDS possibly on the verge of a new phase, where drug-resistant strains become harder to treat, Dr. Frieden was right to go public. Dr. Alfred Sommer, the dean of the Bloomberg School of Public Health at Johns Hopkins in Baltimore, said health officials often did not have the luxury of waiting for full scientific information before acting.
“For most things we do, we do not have ironclad proof one way or the other,” he said.
Dr. Frieden said that his initial announcement clearly contained cautions and unknowns, but that his actions were necessary given the potential public health effects.
“We had enough clinical and scientific information to warrant making the announcement because of the immediate implications for the community, and for doctors practicing in New York City,” he said.
“We run the risk of either being a dollar short and a day late, or shouting fire in a crowded theater,” said Dr. Michael T. Osterholm, director of for the Center for Infectious Disease Research and Policy at the University of Minnesota. “The question is,” he said of Dr. Frieden, “is he a prophet today or is he a prophet 10 years from now?”
The debate is likely to grow louder beginning tomorrow in Boston when 3,800 of the world’s top AIDS experts are to meet in a conference to discuss an array of new scientific findings. Long after the deadline for submissions of reports had passed, the doctors who handled the New York City case, Dr. David D. Ho and Dr. Martin Markowitz, asked for a waiver to discuss the findings about the possible strain they had made at the Aaron Diamond AIDS Research Center in Manhattan.
After much wrangling, the organizers of the meeting agreed to hold an unusual special session for the disagreement about the city’s announcement.
But scientists were not the only ones upset about the city’s actions. Some gay activists asserted that Dr. Frieden was using the possible new strain as a scare tactic to get gay men to practice safe sex, an accusation he denied.
Charles King, the president of Housing Works, an AIDS support group, said the announcement could be used to demonize the gay lifestyle and accused Dr. Frieden of having wanted to change regulations regarding H.I.V. testing for a long time. The Community H.I.V./AIDS Mobilization
Project, based in New York, said the link between the spread of the possible new strain and the use of crystal methamphetamine was unproven, and suggested that the city had ignored the “underlying issues” behind the spread of the virus, like discrimination, poor housing and unemployment.
“Rather than increasing awareness of the risks of unsafe sex and crystal use, the Health Department risks stigmatizing gay men as crazed drug addicts carelessly or wantonly spreading a killer bug,” Community H.I.V./AIDS Mobilization Project said in a statement. “In this case, the Health Department seems to offer little to the understanding of the root causes and potential solutions to drug use apart from the discredited strategy of Nancy Reagan, ‘Just say no.’ “
Martin Delaney, the founding director of Project Inform, a nonprofit AIDS foundation, said the city had been needlessly alarmist. “By pushing this out early, the public health department set off panic nationwide, before the scientific community had had a chance to see the scientific data,” Mr. Delaney said.
Several gay activists said Dr. Frieden was motivated, in part, by a close relationship with the Aaron Diamond Center, a charge that city officials dismissed as ridiculous. The center was created in 1988 to study the basic science of AIDS as a joint venture of the city’s Health Department, the New York University School of Medicine, and the Aaron Diamond Foundation, a philanthropic organization. Upon becoming commissioner in 2002, Dr. Frieden joined the center’s board, as had all his predecessors since the founding of the institution. Health Department officials say he has no financial interest in the center.
Dr. Ho, then a relatively unknown 37-year-old researcher fresh from Harvard and U.C.L.A., was hired to run the center in 1989 and immediately attracted attention. With more money at his disposal than most other research institutions, Dr. Ho became the object of envy as top-flight
scientists lined up to join his center. Within a few years, Dr. Ho’s team won international publicity, challenging long-held theories about AIDS and reporting new evidence about the way the AIDS virus works in the body.
However, Dr. Ho has been criticized for trumpeting findings that other scientists say later proved wrong. For instance, Dr. Ho and colleagues strongly suggested, without explicitly stating it as fact, that a treatment with drug cocktails could cure AIDS by eradicating the virus from a patient’s blood. Since then, it has become clear that the virus lurks in hidden sanctuaries in the body, making it all but impossible to eradicate H.I.V. with currently licensed drugs.
Critics have also charged that ViroLogic, the lab that did some of the testing for the Diamond Center and the Health Department in the most recent case, is using the case to promote its services. The Monday after Dr. Frieden’s Friday news conference, ViroLogic issued a news release calling attention to its work performing the test for drug resistance. Dr. Ho, who was quoted in the release, serves on the scientific advisory board of ViroLogic. His brother, Sidney Ho, does marketing work for the company and once was the head of its communications department.
William D. Young, the chairman and chief executive of ViroLogic, said there was no effort by Dr. Ho to promote ViroLogic through this case. He said the company’s scientific advisers “are very aware of their scientific reputations and that’s paramount to them. At some times I prefer them to be promotional but they are not.” Mr. Young said ViroLogic issued the news release to make the public aware of its role in the testing and its extensive nature.
Dr. Ho said that he has disclosed all of his ties to the company and that any suggestion of impropriety was false.
After Dr. Frieden disclosed the case, reports of similar cases quickly emerged, some of which had been published earlier. For example, Dr. Julio Montaner, a professor of medicine at the University of British Columbia in Vancouver, reported in 2003 in the scientific journal AIDS that two men with a highly drug-resistant strain of H.I.V. might have progressed rapidly to AIDS. Dr. Ho did not contact Dr. Montaner about the case until three days after Dr. Frieden’s news conference.
Dr. Ho said he had searched standard databases for similar cases but did not find Dr. Montaner’s report. After being made aware of the cases and looking into them, he said there were similarities but also significant differences. “Our case was much more dramatic in the history of progression and resistance,” Dr. Ho said.
Dr. Ho, for his part, said, he was accustomed to criticism, but insisted, “We did the right thing in this case.”
Andrew Pollack in Los Angeles and Carol Pogash in San Francisco contributed reporting for this article.